Medicenna Therapeutics Corp. (TSE:MDNA – Get Free Report) traded up 1.6% on Thursday . The stock traded as high as C$1.98 and last traded at C$1.87. 29,147 shares were traded during trading, a decline of 72% from the average session volume of 102,571 shares. The stock had previously closed at C$1.84.
Medicenna Therapeutics Stock Performance
The stock has a market cap of C$142.92 million, a P/E ratio of -4.92 and a beta of 1.21. The firm has a 50 day moving average of C$1.94 and a two-hundred day moving average of C$2.04. The company has a debt-to-equity ratio of 0.06, a quick ratio of 4.65 and a current ratio of 2.51.
Medicenna Therapeutics Company Profile
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors.
Recommended Stories
- Five stocks we like better than Medicenna Therapeutics
- What is a Special Dividend?
- Top 3 Investment Themes to Watch for in 2025
- Top Stocks Investing in 5G Technology
- Mega Buybacks in 2025: Why These 3 Leading Stocks Are Buys
- Industrial Products Stocks Investing
- AMD vs. NVIDIA: The Better Semiconductor Bet for 2025
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
